

# 高雄榮民總醫院

## 胃癌診療指引

2021年03月09日 第一版

胃癌醫療團隊擬訂

注意事項：這個診療原則主要作為醫師和其他保健專家診療癌症病人參考之用。假如你是一個癌症病人，直接引用這個診療原則並不恰當，只有你的醫師才能決定給你最恰當的治療。

# 修訂指引

- 本共識參考國家衛生研究院於2012年1月出版之胃癌臨床指引、JGCA及其他參考文獻，於2021.03.09由胃癌團隊成員共同討論後修訂。

# 會議討論

上次會議：2020/02/04

本共識與上一版的差異

上一版	新版
1.臨床分期為身體狀況適合手術且腫瘤是有機會切除的治療選項是手術(±IIHC)。 Page 4	1.臨床分期為身體狀況適合手術且腫瘤是有機會切除的治療選項新增化學治療(±放射治療)選項。 Page 4
2. ESD的criteria 拼字錯誤。 Page 7	2.修正拼字 Page 7
3.手術建議表(1)原分cT1、cT2/T3/T4a跟T4b。 Page 7	3.手術建議表(1)合併cT2/T3/T4a跟T4b，並新增先作neoadjuvant→手術+/- HIPEC選項。 Page 7
4. HIPEC適應症建議表有三項Regimen。 Page 9	4.刪除low dose paclitaxel。 Page 9
5.轉移癌化學治療處方原有:TS-1、UFUR、EOX、XO、FP、mDCF、D-FOX、DOX。 Page 14	5.轉移癌化學治療處方新增:DS。 Page 14
6.無。	6.新增三線化學治療處方:Lonsuf。 Page 17
7.無。	7.新增NIPS的處方:low dose paclitaxel。 Page 18


# 胃腺癌

## 高雄榮民總醫院 臨床診療指引

2021年第一版

評估	診斷	治療	追蹤
----	----	----	----

- 病史、理學檢查
  - 營養及日常體能狀態
  - 胸部X光
  - 血液常規
  - 電解質及肝腎功能
  - 腫瘤指標 (CEA, Ca19-9)
  - \* 腹部(胃)電腦斷層攝影
  - 上消化道內視鏡及生檢 (Biopsy)
- 
- 必要時評估→
  - \* 正子攝影
  - 內視鏡超音波
  - 腹腔鏡
  - 上消化道攝影
- 
- \* 與期別相關之主要檢查



- 追蹤(p5-6 Table-1)
- 手術(p7-8 Table-2)
- IHC(p9 Table-3)
- 化學治療(p10-18 table-4.1、4.2、4.3、4.4、4.5、4.6)
- 標靶治療(p19 table-5)
- 免疫治療(p20 table-6)
- 放射治療(p21 table-7)
- 癌症藥物停藥準則(p22 table-8)

# 胃腺癌

高雄榮民總醫院  
臨床診療指引

2021年第一版

評估	診斷	治療	追蹤
<p>手術結果</p> <ul style="list-style-type: none"> <li>R0切除</li> <li>R1切除</li> <li>R2切除</li> <li>遠端轉移</li> </ul>	<ul style="list-style-type: none"> <li>Tis, T1N0</li> <li>T2, T3, T4 或淋巴轉移</li> <li>化學治療 (±放射治療)</li> <li>化學治療 (±放射治療)</li> </ul>	<ul style="list-style-type: none"> <li>觀察</li> <li>觀察或輔助性化學治療 (±放射治療)</li> <li>見-p6 轉移或復發胃癌</li> </ul>	<ul style="list-style-type: none"> <li>※ GOT/GPT, ALP, Alb, CBC, CEA, CA199</li> <li>Every 3 months for 2 years</li> <li>Every 6 months for 3-5 years then annually</li> <li>※ CXR</li> <li>Every 6 months for 5 years then annually</li> <li>※ Abdominal Sono</li> <li>Every 6 months for 5 years then as clinically indicated</li> <li>※ Panendoscope</li> <li>Annually for 5 years then as clinically indicated</li> <li>※ Abdominal CT</li> <li>Annually for 5 years then as clinically indicated</li> </ul>


Table-1 術後追蹤建議表

# 胃腺癌

高雄榮民總醫院  
臨床診療指引


2021年第一版

評估	診斷	治療	追蹤
----	----	----	----







分數	ECOG
0	無症狀
1	有症狀，但可以正常活動，對生活無影響
2	可以照顧自己但無法工作，躺在床上的時間 < 50%的工作時間
3	躺在床上的時間 > 50%的工作時間
4	長期完全臥床
5	死亡

Table-2手術建議表(1)



### Table-2手術建議表(2)

Type of Gastrectomy with lymph node dissection		
Gastrectomy	Extent of LN dissection	圖表
Total gastrectomy	D1 :Nos 1-7 D1+:D1+Nos 8a,9,11p D2 :D1+Nos 8a,9,10,11p,11d,12a For tumor invading the esophagus D1+Includes No,110 <sup>1</sup> . D2 includes Nos.19,20,110,and 111	 
Distal gastrectomy	D1 :Nos 1,3,4sb,4d,5,6,7 D1+:D1+Nos 8a, 9 D2 :D1+Nos 8a,9,11p,12a	 
Pylorus-preserving gastrectomy	D1 :Nos 1,3,4sb,4d,6,7 D1+:D1+Nos 8a, 9	
Proximal gastrectomy	D1 :Nos 1,2,3a,4sa,4sb,7 D1+:D1+Nos 8a, 9,11p	



## Table-3 IHC 適應症建議表

### Hyperthermic IntraPeritoneal Chemotherapy (HIPEC)

※Indication :  $\geq$  T4a

※Regimen 1: (41-42°C for 20-60 minutes )

Cisplatin 90 mg 【IP-1】

Etoposide 90 mg

Mitomycin C 30 mg

Reference :No 4-7/strength of Evidence :Level I

※Regimen 2: (41-42°C for 20-60 minutes)

Paclitaxel 80mg/m<sup>2</sup> 【IP Paclitaxel, high dose】

Reference : No 28/strength of Evidence :Level IIB

Table-4.1 化學治療處方建議表：輔助化療

Adjuvant chemotherapy	Schedule	Reference (No)/ strength of Evidence
<b>TS-1</b> 40-60mg bid ( <b>ACTS-GC trial</b> ) (po 4 weeks on, 2 weeks off/or po 2 weeks on, 1 weeks off) BSA >1.5m <sup>2</sup> : 60mg bid; 1.25m <sup>2</sup> -1.5m <sup>2</sup> : 50mg bid; <1.25m <sup>2</sup> : 40mg bid	Q42 d /cycle For 12 months	No.8 / Level I
<b>UFUR</b> 2# po bid ( <b>NSAS-GC trial</b> )	For 16 months	No.9 / Level I
<b>Oxaliplatin</b> 130 mg/m <sup>2</sup> , IV,D1 <b>【 XO 】</b> ( <b>CLASSIC trial</b> ) <b>Xeloda</b> 2#po QAM(Day1-14) ,3# PM (Day1-14) (825-1000mg/m <sup>2</sup> )	Q21 d x 8-12cycles	No.10 / Level I
<b>Oxaliplatin</b> 130mg/m <sup>2</sup> , IV, D1 <b>【 EOX】</b> <b>Epirubicin</b> 50mg/m <sup>2</sup> , IV, D1 <b>Xeloda</b> 625mg/m <sup>2</sup> bid x 3 weeks	Q21 d x 8 cycles	No.11 / Level I
<b>Oxaliplatin</b> 100mg/m <sup>2</sup> , IV, D1 <b>【SOX】</b> <b>TS-1</b> 40-60mg bid ,PO, D1~14 BSA >1.5m <sup>2</sup> : 60mg/bid ; 1.25-1.5m <sup>2</sup> : 50mg/bid ; <1.25m <sup>2</sup> : 40mg/bid	TS-1(2 weeks on, 1 weeks off) →SOX Q21 d x 8 cycles	No.31 / Level II
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV, D1 <b>【DOX】</b> <b>Oxaliplatin</b> 100mg/m <sup>2</sup> , IV, D1 <b>Xeloda</b> 1.25#/m <sup>2</sup> ( 625mg/m <sup>2</sup> ) PO, D1-14	Q21d x 8 cycles	No.34 / Level IB

Table-4.1 化學治療處方建議表：輔助化療

Adjuvant chemotherapy	Schedule	Reference (No)/ strength of Evidence
<b>Taxotere</b> 50mg/M2, IV, D1 <b>【FLOT】</b> <b>Oxaliplatin</b> 85mg/M2, IV, D1 <b>Leucovorin</b> 200mg/M2, IV, D1 <b>5-FU</b> 2600mg/M2, IV, D1	Q14d x 4-8 cycles 術前4cycles 術後4cycles	No.35 / Level I
<b>Oxaliplatin</b> 85mg/M2, IV, D1 <b>【FOLFOX】</b> <b>Leucovorin</b> 400mg/M2, IV, D1 <b>5-FU</b> 400mg/M2, IV, D1 , <b>5-FU</b> 2400-3000mg/M2, IV, D1-2	Q14d x 8-12cycles	No.36 / Level I
<b>TS-1 + docetaxel</b> *stage III <b>【DS】</b> Docetaxel 40mg/m2,IV,D1 TS-1 80-120mg/day,PO bid ,D1~14 BSA >1.5m <sup>2</sup> : 60mg/bid ; 1.25- 1.5m <sup>2</sup> : 50mg/bid ; <1.25m <sup>2</sup> : 40mg/bid	Q21d x 8 cycles 1 <sup>st</sup> cycle TS-1 2 <sup>nd</sup> ~7 <sup>th</sup> TS-1+ docetaxel 8 <sup>th</sup> 起TS-1 up to 1year	No.37 / Level I

Table-4.2 化學治療處方建議表：術前輔助化療

Neoadjuvant chemotherapy	Schedule	Reference (No)/ strength of Evidence
<b>Oxaliplatin</b> 130 mg/m <sup>2</sup> , IV,D1 <b>【 XO 】 (CLASSIC trial)</b> <b>Xeloda</b> 2#po QAM(Day1-14) ,3# PM (Day1-14) (825-1000mg/m <sup>2</sup> )	Q21 d	No.26 / Level IIB
<b>Oxaliplatin</b> 130mg/m <sup>2</sup> , IV, D1 <b>【 EOX】</b> <b>Epirubicin</b> 50mg/m <sup>2</sup> , IV, D1 <b>Xeloda</b> 625mg/m <sup>2</sup> bid X 3 weeks	Q21 d	No.11 / Level I
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV, D1 <b>【DOX】</b> <b>Oxaliplatin</b> 100mg/m <sup>2</sup> , IV, D1 <b>Xeloda</b> 1.25#/m <sup>2</sup> ( 625mg/m <sup>2</sup> ) PO, D1-14	Q21d x 2-4 cycles	No.34 / Level IB
<b>Taxotere</b> 50mg/M <sup>2</sup> , IV, D1 <b>【FLOT】</b> <b>Oxaliplatin</b> 85mg/M <sup>2</sup> , IV, D1 <b>Leucovorin</b> 200mg/M <sup>2</sup> , IV, D1 <b>5-FU</b> 2600mg/M <sup>2</sup> , IV, D1	Q14d x 4-8 cycles 術前4cycles 術後4cycles	No.35 / Level I
<b>Oxaliplatin</b> 85mg/M <sup>2</sup> , IV, D1 <b>【FOLFOX】</b> <b>Leucovorin</b> 400mg/M <sup>2</sup> , IV, D1 <b>5-FU</b> 400mg/M <sup>2</sup> , IV, D1 , <b>5-FU</b> 2400-3000mg/M <sup>2</sup> , IV, D1-2	Q14d /cycle	No.36 / Level I

Table-4.3 化學治療處方建議表：轉移癌

Chemotherapy for unresectable/recurrent disease	Schedule	Reference (No)/ strength of Evidence
<b>TS-1</b> 40-60mg bid (po 4 weeks on, 2 weeks off/or po 2 weeks on, 1 weeks off) BSA $\geq 1.5\text{m}^2$ : 60mg bid, $1.25\text{m}^2$ - $1.5\text{m}^2$ : 50mg bid, < $1.25\text{m}^2$ : 40mg bid	Q42 d /cycle For 12 months	No.8 / Level I
<b>UFUR</b> 2# po bid	For 16 months	No.13 / Level I
<b>Oxaliplatin</b> 130mg/m <sup>2</sup> , IV, D1 <b>【EOX】</b> <b>Epirubicin</b> 50mg/m <sup>2</sup> , IV, D1 <b>Xeloda</b> 625mg/m <sup>2</sup> bid X 3 weeks	Q21 d x 8 cycles	No.11 / Level I
<b>Oxaliplatin</b> 130 mg/m <sup>2</sup> , IV,D1 <b>【XO】</b> <b>Xeloda</b> 2#po QAM(Day1-14) ,3# PM (Day1-14) (825-1000mg/m <sup>2</sup> )	Q21 d x 8-12cycles	No.1, 14 / Level II
<b>Cisplatin</b> 60-80 mg/m <sup>2</sup> , IV, D1 <b>【FP】 【FP-1】</b> <b>5-FU</b> 800-1000mg/m <sup>2</sup> , IV, D1-5	Q21 d x 8-12cycles	No.15 / Level II

Table-4.3 化學治療處方建議表：轉移癌

Chemotherapy for unresectable/recurrent disease	Schedule	Reference (No)/ strength of Evidence
<b>Docetaxel</b> 40mg/m <sup>2</sup> , IV, D1 <b>【mDCF】</b> <b>CDDP</b> 40mg/m <sup>2</sup> , IV, D3 <b>5-FU</b> 2000mg/m <sup>2</sup> , IV, D1-2	Q14d x 6-8 cycles /Until progression	No.29 /Level II
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV, D1 <b>【D-FOX】</b> <b>Oxaliplatin</b> 85mg/m <sup>2</sup> , IV, D1 <b>5-FU</b> 1100mg/m <sup>2</sup> , IV, D1-2	Q14d x 6-8 cycles /Until progression	No.30 /Level II
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV, D1 <b>【DOX】</b> <b>Oxaliplatin</b> 100mg/m <sup>2</sup> , IV, D1 <b>Xeloda</b> 1.25#/m <sup>2</sup> ( 625mg/m <sup>2</sup> ) PO, D1-14	Q21d x 6-8 cycles /Until progression	No.34 /Level IB
<b>TS-1 + docetaxel</b> <b>【DS】</b> Docetaxel 40mg/m <sup>2</sup> ,IV,D1 TS-1 80-120mg/day,PO bid ,D1~14	Q21d x 8 cycles/ Until progression	No.37 / Level I

Table-4.4 化學治療（二線）處方建議表

Chemotherapy for unresectable/recurrent disease	Schedule	Reference (No)/ strength of Evidence
<b>Irinotecan</b> 150 mg/m <sup>2</sup> , IV, D1	Q14d /cycle Until progression	No.20, 21 /Level I
<b>Docetaxel</b> 60 – 75 mg/m <sup>2</sup> , IV, D1	Q21d /cycle Until progression	No.21, 22 /Level I
<b>Paclitaxel</b> 80 mg/m <sup>2</sup> , IV, D1, D8, D15	Q28d/cycle Until progression	No.23 /Level I
<b>Ramucirumab</b> (8 mg/kg, IV, D1, D15) + <b>Paclitaxel</b> (80 mg/m <sup>2</sup> , IV, D1, D8, D15)	Q28d/cycle Until progression	No. 25 /Level I
<b>Docetaxel</b> 40mg/m <sup>2</sup> ,IV ,D1 <b>【mDCF】</b> <b>CDDP</b> 40mg/m <sup>2</sup> ,IV ,D3 <b>5-FU</b> 2000mg/m <sup>2</sup> ,IV ,D1-2	Q14d /cycle Until progression	No.29 /Level II
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV ,D1 <b>【D-FOX】</b> <b>Oxaliplatin</b> 85mg/m <sup>2</sup> ,IV,D1 <b>5-FU</b> 1100mg/m <sup>2</sup> ,IV ,D1	Q14d /cycle Until progression	No.30 /Level II

Table-4.4 化學治療（二線）處方建議表

Chemotherapy for unresectable/recurrent disease	Schedule	Reference (No)/ strength of Evidence
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV, D1 <b>【DOX】</b> <b>Oxaliplatin</b> 100mg/m <sup>2</sup> , IV, D1 <b>Xeloda</b> 1.25#/m <sup>2</sup> ( 625mg/m <sup>2</sup> ) PO, D1-14	Q21d x 6-8 cycles /Until progression	No.34/Level IB



Table-4.5 化學治療（三線）處方建議表

Chemotherapy for unresectable/recurrent disease	Schedule	Reference (No)/ strength of Evidence
Oral Lonsurf 35 mg/m <sup>2</sup> , BID (D1-5 & D8-12); 前2週服用5天休2天，後2週休息	Q28d/cycle /Until progression	No.38/ Level I

**Table-4.6 化學治療 (NIPS) 處方建議表:**

<b>Chemotherapy for unresectable/recurrent disease</b>	<b>Schedule</b>	<b>Reference (No)/ strength of Evidence</b>
<b>Paclitaxel      20mg/m<sup>2</sup>/week      【IP Paclitaxel, low dose】</b>	as clinically indicated	<b>No 27/strength of Evidence :Level IIA</b>

Table-5 標靶治療處方建議表

for unresectable/recurrent disease	Schedule	Reference (No)/ strength of Evidence
<b>Trastuzumab</b> 6-8mg/kg ,IV ,D1 <b>CDDP</b> 80mg/m <sup>2</sup> ,IV ,D1 / <b>Carboplatin</b> AUC4-6mg ,IV ,D1 <b>Xeloda</b> 1000mg/m <sup>2</sup> PO,BID ,D1~14 / <b>5-FU</b> 800mg/m <sup>2</sup> ,IV ,D1~5 使用條件： Her-2/neu免疫染色3+, 或2+且FISH positive for amplification	8 mg/kg loading dose, 6 mg/kg every 3 weeks Until progression	No 16 / Level I
<b>Ramucirumab</b> 8 mg/kg, IV, D1	Q14d/cycle Until progression	No. 24 / Level I
<b>Ramucirumab</b> (8 mg/kg, IV, D1, D15) + <b>Paclitaxel</b> (80 mg/m <sup>2</sup> , IV, D1, D8, D15)	Q28d/cycle Until progression	No. 25 /Level I

# 胃腺癌

高雄榮民總醫院  
臨床診療指引

2021年第一版

Table-6 免疫治療處方建議表

Nivolumab	3mg/kg	D1	Q2W	Until progression	(Ref. No 32/ Level II)
Pembrolizumab	200mg	D1	Q3W	Until progression	(Ref. No 33/ Level II)

**Table-7 放射治療處方建議表**

<p>※ <b>Protocol of adjuvant chemoradiotherapy</b></p>	<p>※.For R0 resection <math>\geq</math> stage IIA                  ※ For R1 resection and R2 resection</p>
<p><b>Radiation therapy:</b>                  Target volume: tumor/ gastric bed and pertinent nodal group Dose: 45-50.4 Gy /(1.8 Gy/day)  <b>Chemotherapy regimen:</b>                  5-FU (400 mg/m<sup>2</sup> per day) and leucovorin (20 mg/m<sup>2</sup> per day) on the first four and the last three days of RT. <b>Reference :No 17/strength of Evidence :level 1</b></p>	
<p>※ <b>Protocol of chemoradiation as the primary treatment</b></p>	<p>※ For medically fit patients but unresectable cancer without distant metastasis                  ※ For medically unfit patients without distant metastasis</p>
<p><b>Radiation therapy:</b>                  Target volume: tumor/ gastric bed and pertinent nodal group Dose: 45-50.4 Gy /(1.8 Gy/day)  <b>Chemotherapy regimen:</b>                  5-FU (400 mg/m<sup>2</sup> per day) and leucovorin (20 mg/m<sup>2</sup> per day) on the first four and the last three days of RT. <b>Reference :No 17/strength of Evidence :level 1</b></p>	

## Table-8 癌症藥物停藥準則

影像學檢查，腫瘤有變大或轉移變多，應停止或改變治療方式。

## Reference

1. NCCN Clinical Practice Guideline in Oncology, Gastric cancer , **Version 2.2021**
2. 國家衛生研究院 胃癌臨床診療指引2012年第1版
3. 日本胃癌診療指引2010年第3版
4. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. *Ann Surg Oncol* 2007;14:2702-2713.
5. Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomised controlled study. *Hepatogastroenterol* 2001; 48:1776–82.
6. Deng-Hai Mi , Zheng Li , Ke-Hu Yang et al. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. *Int J Hyperthermia*. 2013;29(2):156-67
7. Kang LY et al. Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant chemotherapy for advanced gastric cancer patients with serosal invasion. *J Chin Med Assoc*. 2013 Aug;76(8):425-31.
8. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med*. 2007;357:1810–20.
9. T.Nakajima,T.Kinoshita,A.Nashimoto et al:Randomized controlled trail of adjuvant uracil –tegafur versus surgery alone for serosa –negative ,locally advanced gastric cancer .*British Journal of Surgery* 2007, vol. 94:1468-1476.
10. Sung Hoon Noh, Sook Ryun Park, Han-Kwang Yang et al: Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 2014 Nov;15(12):1389-96
11. K Sumpter,C Harper-Wynne,D Cunningham et al:Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.*British journal of Cancer*2005, vol.92:1976-1983.
12. Wasaburo Koizumi,Hiroyuki Narahara,Takuo Hara et al:S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase III trial . *Lancet oncology* .2008 vol.3.215-221.

13. N.F.Aykan & E.Idlevich:The role of UFT in advanced gastric cancer .Annals of Oncology 2008 ,vol.19.1045-1052.
14. Kim GM, Jeung HC, Rha SY et al. A randomized phase II trial of S-1 oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eu J Cancer* 2012;48:518-526.
15. Park SC and Chun HJ. Chemotherapy for advanced gastric cancer:Review and update of current practices. *Gut and Liver* 2013, vol 7. 385-393.
16. Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al:Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial.*Lancet*.2012.vol.376.687-697.
17. Macdonald JS; Smalley SR; Benedetti J; Hundahl SA; Estes NC; Stemmermann GN; Haller DG; Ajani JA; Gunderson LL; Jessup JM; Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction [Intergroup trial 0016]. *N Engl J Med* 2001 Sep 6;345(10):725-30.
18. Chikara Kunisaki, MD, PhD, Hirochika Makino, MD, PhD, Jun Kimura, MD et al. Impact of lymphovascular invasion in patients with stage I gastric cancer. *Surgery* 2010;147:204-11.
19. Chunyan Du . Ye Zhou . Kai Huang . Guangfa Zhao . Hong Fu . Yingqiang Shi. Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy. *J Gastrointest Surg*(2011) 15:2153-2158.
20. Peter C. Thuss-Patience et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)*Eur J Cancer*. 2011 Oct;47(15):2306-14
21. Jung Hun Kang et al. Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone. *J Clin Oncol* 30:1513-1518; 2012
22. Hugo E R Ford et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol* 2014; 15: 78–86.



23. Shuichi Hironaka et al. Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial. *J Clin Oncol* 31:4438-4444; 2013.
24. Charles S Fuchs et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet* 2014; 383: 31–39
25. Hansjochen Wilke et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol* 2014; 15: 1224–35.
26. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012;48:518-526.
27. Hironori Yamaguchi et al. Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes. *World Journal of Gastrointestinal Oncology* 2015;7(11):285-291.
28. Motohiro Imano et al, Phase II Study of Single Intraperitoneal Chemotherapy Followed by Systemic Chemotherapy FOR Gastric Cancer with Peritoneal Metastasis. *J Gasyrointest Surg* 2012;16:2190-2196.
29. Manish A. Shah et al, Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. *Journal of clinical oncology* 2015;33:3874-3879.
30. Mariela A. Blum Murphy, MD et al, A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. *American Journal of Clinical Oncology* 2018 ;41:321-325.
31. Kohei Shitara et al, Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. *Gastric Cancer*.2015 Dec 20(1)DOI:10.1007/s10120-015-0581-1
32. Yoon-Koo Kang et al, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet* .2017 Dec 2;390(10111):2461-2471

33. Lola Fashoyin-Aje et al, FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. *Oncologist*.2018 Aug 17 ; 2018-0221
34. E.Van Cutsem et al, Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. *Annals of Oncology* 26: 149–156, 2015.
35. Al-Batran SE et al, Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. *Lancet Oncol*.2016 Dec;17(12):1697-1708.
36. Liu M, Hu G, Wang Y, Guo J, Liu L, Han X, Wang Z, Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer. *OncoTargets and Therapy*.2018;11 Pages 375-381.
37. Kazuhiro Yoshida. et al, Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial . *Journal of Clinical Oncology* 2019;37(15):1296-1304.
38. **David H. Ilson, MD, PhD. et al, Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy . *JAMA Oncol*. 2019 Oct 10;6(1):e193531.**